Morgan Stanley analyst James Faucette maintained an Equal-Weight rating and cut the price target from $372 to $340 on June 12 ...

Dyne updates DYNE-101 trial timeline, reports strong 12-month data, and receives FDA Breakthrough Therapy status for treating ...

U.S. dollar weakens, boosting the appeal of gold stocks and driving up prices of producers like Agnico Eagle, Newmont, and ...

AbbVie's Phase 3 VERONA trial in HR-MDS showed no overall survival benefit for venetoclax-azacitidine; existing uses of ...

What Happened: Zhu, SVP at Tesla, exercised stock options for 15,000 shares of TSLA stock. This information was disclosed in ...

Compared to its top 4 peers, Amazon.com has a stronger financial position indicated by its lower debt-to-equity ratio of 0.44 ...

Short interest is the number of shares that have been sold short but have not yet been covered or closed out. Short selling ...

Short interest is the number of shares that have been sold short but have not yet been covered or closed out. Short selling ...

PureCycle Technologies shares are soaring on a $300 million capital raise. Global expansion plans for plastic recycling ...

Meme coin heavyweights Dogecoin (CRYPTO: DOGE) and Shiba Inu (CRYPTO: SHIB) saw sharp daily losses as sentiment across the ...

Processa Pharmaceuticals' stock is surging after licensing a gastroparesis drug to Intact Therapeutics. The deal promises ...

Mineralys reports Phase 2 trial success for lorundrostat, showing BP and kidney improvements in CKD patients with favorable ...